Authors

Latest:

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.

Oludamilola (Lola) A. Olajide, MD

Latest:

Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Omar Al Ustwani, MD

Latest:

Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia

Abelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.

Omar Hafez, MS, MBA

Latest:

Signs Point to Better Market Conditions for Biosimilars

Even though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.

Omar Nadeem, MD

Latest:

Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Omid A. Hamid, MD

Omid Hamid, MD, is a professor of medicine at Cedars-Sinai. He is also director of clinical Research and Immunotherapy and director of Cutaneous Oncology and Melanoma at the The Angeles Clinic and Research Institute, both in Los Angeles, California.

Latest:

Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma

Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.

Omid Hamid, MD

Latest:

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

OncLive

Latest:

Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape

On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape. Caroline Robert, MD, PhD, led the discussion, obtaining perspectives on the available evidence about immunotherapy options and insights into treatment preferences for high-risk cutaneous squamous cell carcinoma that is either locally advanced (laCSCC) or metastatic (mCSCC) and advanced/metastatic cutaneous melanoma.

OncLive Breast PX-ESMO-10/5/17 Adam M. Brufsky, MD, PhD, University of Pittsburgh Cancer Institute

OncLive Nursing

Latest:

Noninvasive Stool Test Effectively Detects Colon Cancer

The iFOBT test examines the stool for hidden blood, which could come from anywhere in the GI tract, and possibly indicates a colon tumor or precancerous growths known as polyps.

OncLive Staff

Latest:

Five Under 5: Top Oncology Videos for the Week of 12/7

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

OncLive Staff Writer

Latest:

FDA Accepts Sacituzumab Govitecan Application for TNBC

The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.

OncLive TV

Latest:

Dr Grunwald on a Real-World Study of Risk Factors For Disease Progression in PV

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

OncNurse

Latest:

ASCO Updates Guidelines on Bone-Modifying Drugs in Breast Cancer

ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.

Oncology &amp

Latest:

Age Cutoff for Pap Tests Questioned

More than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006

Oncology & Biotech News

Latest:

Study Shows No Survival Benefit of Cetuximab Over Cisplatin-Based Chemoradiation in Head and Neck Cancers

Patients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.

Oncology & Biotech News Editors

Latest:

Chemotherapy Foundation Symposium Overview

2008's Chemotherapy Foundation Symposium

Oncology Practice

Ophira Ginsburg, MD

Latest:

Dr. Ginsburg Discusses Cervical Cancer Screening Techniques

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer screening techniques.

Ophira M. Ginsburg, MSc, MD,

Latest:

Dr. Ginsburg on Genetic Testing in Ovarian Cancer Families

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.